Quarter
Charts

MARIMED INC.

MRMD

CIK 0001522767 · Quarterly mode · latest period FY2025 (Q4) (ending 2025-12-31) · sourced from SEC EDGAR

At a glance · FY2025 (Q4)

Revenue
$42M
↑+7.5% +$3Mvs FY2024 (Q4)
Operating Income
$8M
↓-18.1% -$2Mvs FY2024 (Q4)
Net Income
$6M
↑+81.4% +$3Mvs FY2024 (Q4)
Gross Profit
$11M
↓-15.7% -$2Mvs FY2024 (Q4)

Quality Score

Quality score

6-dimension fundamental snapshot · latest annual filed values · S&P 500 calibration

Poor
25/100
  • Profitability
    0ROIC -1.7% (10% = solid, 20%+ = moat)
  • Liquidity
    25Current Ratio 1.00 (above 1.5 = solid)
  • Leverage
    24D/E 1.52 (under 0.5 = conservative)
  • Efficiency
    45Asset Turnover 0.78x (1.0+ = capital-efficient)
  • Growth
    42Revenue YoY +7.5% (10% = solid, 25%+ = elite)
  • Margin Trend
    14Op Margin 3.9% · trend -2.1pts (4Q avg vs prior 4Q)

Calibrated to S&P 500 medians. Each sub-score is computed from a single CFA-grade ratio (Profitability = ROIC, Liquidity = Current Ratio, Leverage = D/E, Efficiency = Asset Turnover, Growth = Revenue YoY, Margin Trend = 4Q operating-margin avg vs prior 4Q). Overall = simple mean.

DCF intrinsic value

DCF intrinsic value

two-stage Gordon model

Project MRMD's free cash flow forward, discount back at your hurdle rate, divide by diluted shares. Edit the assumptions to see how sensitive the intrinsic value is.

8%

Trailing CAGR unavailable; default 8%

10%

10% is a common all-equity benchmark for US large-caps

2.5%

Should be ≤ long-run GDP growth (~2.5% nominal)

5

5-year explicit projection + perpetuity terminal

Intrinsic value per share
$0.29
Total enterprise IV
$112M
Diluted shares
0.39B
Terminal PV
$81M (72% of total)
Year-5 FCF
$10M
YearProjected FCFDiscounted PV
+1$7M$6M
+2$8M$6M
+3$8M$6M
+4$9M$6M
+5$10M$6M
Terminal$131M$81M

DCF outputs are HIGHLY sensitive to growth + WACC assumptions. A 1pp WACC change can shift IV by 20%+. Use this as a sanity-check vs market price, not a target — and always cross-check the underlying FCF source (EDGAR cashflow statement, latest annual). Margin of safety convention: 30-50% discount to IV before buying.

Capital allocation · trailing 4 quarters

how the company spent its cash
Capex (TTM)
$1M
investment in PP&E
Stock-based comp (TTM)
$2M
non-cash dilution

Balance sheet · 2025-12-31

latest filed snapshot
Total assets
$203M
everything owned
Total liabilities
$138M
everything owed
Stockholders' equity
$50M
shareholder claim
Net debt
$69M
LT debt minus cash

Recent performance · 60 quarters

Revenue↑+7.5% +$3M
$42M
Net Income↓-193.0% -$2M
$-3M
Free Cash Flow↑+421.0% +$4M
$3M
Operating Margin↑+0.6pts
3.9%

Drill down

MRMD Sankey

See MARIMED INC.'s revenue flow into every line item of the income statement and balance sheet — every dollar accounted for, with prior-period comparison.

Open Sankey

MRMD Charts

60 quarters of historical line items — Income, Cash Flow, Balance Sheet, plus margins. Click any chart for the trend dialog.

Open Charts

MRMD Key Metrics

EPS, BVPS, FCF/Share, ROE, ROA, ROIC, D/E, Current Ratio, Quick Ratio, Asset Turnover — 10 CFA-grade fundamentals derived from EDGAR data.

Open Key Metrics